1
|
Poddutoori R, Aardalen K, Aithal K, Barahagar SS, Belliappa C, Bock M, Chelur S, Gerken A, Gopinath S, Gruenenfelder B, Kiffe M, Krishnaswami M, Langowski J, Madapa S, Narayanan K, Pandit C, Panigrahi SK, Perrone M, Potakamuri RK, Ramachandra M, Ramanathan A, Ramos R, Sager E, Samajdar S, Subramanya HS, Thimmasandra DS, Venetsanakos E, Möbitz H. Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action. J Med Chem 2022; 65:4350-4366. [PMID: 35195996 DOI: 10.1021/acs.jmedchem.1c02192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active compounds that showed equipotent inhibition of WT MEK1/2 and a panel of MEK1/2 mutant cell lines. Using a structure-based approach, the optimization addressed the liabilities by systematic analysis of molecular matched pairs (MMPs) and ligand conformation. Addition of only three heavy atoms to early tool compound 6 removed Cyp3A4 liabilities and increased the cellular potency by 100-fold, while reducing log P by 5 units. Profiling of MAP855, compound 30, in pharmacokinetic-pharmacodynamic and efficacy studies in BRAF-mutant models showed comparable efficacy to clinical MEK1/2 inhibitors. Compound 30 is a novel highly potent and selective MEK1/2 kinase inhibitor with equipotent inhibition of WT and mutant MEK1/2, whose drug-like properties allow further investigation in the mutant MEK setting upon BRAF/MEK therapy.
Collapse
Affiliation(s)
- Ramulu Poddutoori
- Aurigene Discovery Technologies Ltd, 39-40 KIADB Industrial Area, Electronic City Phase II, Bengaluru 560100, India
| | - Kimberly Aardalen
- Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Kiran Aithal
- Aurigene Discovery Technologies Ltd, 39-40 KIADB Industrial Area, Electronic City Phase II, Bengaluru 560100, India
| | | | - Charamanna Belliappa
- Aurigene Discovery Technologies Ltd, 39-40 KIADB Industrial Area, Electronic City Phase II, Bengaluru 560100, India
| | - Mark Bock
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Shekar Chelur
- Aurigene Discovery Technologies Ltd, 39-40 KIADB Industrial Area, Electronic City Phase II, Bengaluru 560100, India
| | - Andrea Gerken
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Sreevalsam Gopinath
- Aurigene Discovery Technologies Ltd, 39-40 KIADB Industrial Area, Electronic City Phase II, Bengaluru 560100, India
| | | | - Michael Kiffe
- Novartis Institutes for BioMedical Research, Basel 4002, Switzerland
| | - Maithreyi Krishnaswami
- Aurigene Discovery Technologies Ltd, 39-40 KIADB Industrial Area, Electronic City Phase II, Bengaluru 560100, India
| | - John Langowski
- Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Sudharshan Madapa
- Aurigene Discovery Technologies Ltd, 39-40 KIADB Industrial Area, Electronic City Phase II, Bengaluru 560100, India
| | - Kishore Narayanan
- Aurigene Discovery Technologies Ltd, 39-40 KIADB Industrial Area, Electronic City Phase II, Bengaluru 560100, India
| | - Chetan Pandit
- Aurigene Discovery Technologies Ltd, 39-40 KIADB Industrial Area, Electronic City Phase II, Bengaluru 560100, India
| | - Sunil Kumar Panigrahi
- Aurigene Discovery Technologies Ltd, 39-40 KIADB Industrial Area, Electronic City Phase II, Bengaluru 560100, India
| | - Mark Perrone
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States
| | - Ravi Kumar Potakamuri
- Aurigene Discovery Technologies Ltd, 39-40 KIADB Industrial Area, Electronic City Phase II, Bengaluru 560100, India
| | - Murali Ramachandra
- Aurigene Discovery Technologies Ltd, 39-40 KIADB Industrial Area, Electronic City Phase II, Bengaluru 560100, India
| | - Anuradha Ramanathan
- Aurigene Discovery Technologies Ltd, 39-40 KIADB Industrial Area, Electronic City Phase II, Bengaluru 560100, India
| | - Rita Ramos
- Global Drug Discovery, Novartis Pharma AG, Basel 4002, Switzerland
| | - Emine Sager
- Novartis Institutes for BioMedical Research, Basel 4002, Switzerland
| | - Susanta Samajdar
- Aurigene Discovery Technologies Ltd, 39-40 KIADB Industrial Area, Electronic City Phase II, Bengaluru 560100, India
| | - Hosahalli S Subramanya
- Aurigene Discovery Technologies Ltd, 39-40 KIADB Industrial Area, Electronic City Phase II, Bengaluru 560100, India
| | | | - Eleni Venetsanakos
- Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Henrik Möbitz
- Novartis Institutes for BioMedical Research, Basel 4002, Switzerland
| |
Collapse
|
2
|
Kim Y, Sengupta S, Sim T. Natural and Synthetic Lactones Possessing Antitumor Activities. Int J Mol Sci 2021; 22:ijms22031052. [PMID: 33494352 PMCID: PMC7865919 DOI: 10.3390/ijms22031052] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Revised: 01/14/2021] [Accepted: 01/16/2021] [Indexed: 12/29/2022] Open
Abstract
Cancer is one of the leading causes of death globally, accounting for an estimated 8 million deaths each year. As a result, there have been urgent unmet medical needs to discover novel oncology drugs. Natural and synthetic lactones have a broad spectrum of biological uses including anti-tumor, anti-helminthic, anti-microbial, and anti-inflammatory activities. Particularly, several natural and synthetic lactones have emerged as anti-cancer agents over the past decades. In this review, we address natural and synthetic lactones focusing on their anti-tumor activities and synthetic routes. Moreover, we aim to highlight our journey towards chemical modification and biological evaluation of a resorcylic acid lactone, L-783277 (4). We anticipate that utilization of the natural and synthetic lactones as novel scaffolds would benefit the process of oncology drug discovery campaigns based on natural products.
Collapse
Affiliation(s)
- Younghoon Kim
- KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Korea;
- Severance Biomedical Science Institute, Graduate School of Medical Science (Brain Korea 21 Project), College of Medicine, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea;
| | - Sandip Sengupta
- Severance Biomedical Science Institute, Graduate School of Medical Science (Brain Korea 21 Project), College of Medicine, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea;
| | - Taebo Sim
- KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Korea;
- Severance Biomedical Science Institute, Graduate School of Medical Science (Brain Korea 21 Project), College of Medicine, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea;
- Correspondence: ; Tel.: +82-2-2228-0797
| |
Collapse
|
3
|
Ellestad GA. (5Z)-7-Oxozeaenol: A novel and potent resorcylic acid lactone kinase inhibitor with a cis-enone Michael acceptor. Chirality 2018; 31:110-117. [PMID: 30565749 DOI: 10.1002/chir.23040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2018] [Revised: 11/09/2018] [Accepted: 11/13/2018] [Indexed: 11/08/2022]
|
4
|
Jana N, Nanda S. Resorcylic acid lactones (RALs) and their structural congeners: recent advances in their biosynthesis, chemical synthesis and biology. NEW J CHEM 2018. [DOI: 10.1039/c8nj02534g] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Resorcylic acid lactones (RALs) are naturally occurring 14-membered macrolactones that constitute a class of polyketides derived from fungal metabolites and that possess significant and promising biological activity.
Collapse
Affiliation(s)
- Nandan Jana
- Department of Chemistry
- Indian Institute of Technology Kharagpur
- Kharagpur
- India
| | - Samik Nanda
- Department of Chemistry
- Indian Institute of Technology Kharagpur
- Kharagpur
- India
| |
Collapse
|
5
|
Piperidylmethyloxychalcone improves immune-mediated acute liver failure via inhibiting TAK1 activity. Exp Mol Med 2017; 49:e392. [PMID: 29147012 PMCID: PMC5704185 DOI: 10.1038/emm.2017.156] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2016] [Revised: 03/27/2017] [Accepted: 04/17/2017] [Indexed: 01/22/2023] Open
Abstract
Mice deficient in the toll-like receptor (TLR) or the myeloid differentiation factor 88 (MyD88) are resistant to acute liver failure (ALF) with sudden death of hepatocytes. Chalcone derivatives from medicinal plants protect from hepatic damages including ALF, but their mechanisms remain to be clarified. Here, we focused on molecular basis of piperidylmethyloxychalcone (PMOC) in the treatment of TLR/MyD88-associated ALF. C57BL/6J mice were sensitized with D-galactosamine (GalN) and challenged with Escherichia coli lipopolysaccharide (LPS, TLR4 agonist) or oligodeoxynucleotide containing unmethylated CpG motif (CpG ODN, TLR9 agonist) for induction of ALF. Post treatment with PMOC sequentially ameliorated hepatic inflammation, apoptosis of hepatocytes, severe liver injury and shock-mediated death in ALF-induced mice. As a mechanism, PMOC inhibited the catalytic activity of TGF-β-activated kinase 1 (TAK1) in a competitive manner with respect to ATP, displaced fluorescent ATP probe from the complex with TAK1, and docked at the ATP-binding active site on the crystal structure of TAK1. Moreover, PMOC inhibited TAK1 auto-phosphorylation, which is an axis in the activating pathways of nuclear factor-κB (NF-κB) or activating protein 1 (AP1), in the liver with ALF in vivo or in primary liver cells stimulated with TLR agonists in vitro. PMOC consequently suppressed TAK1-inducible NF-κB or AP1 activity in the inflammatory injury, an early pathogenesis leading to ALF. The results suggested that PMOC could contribute to the treatment of TLR/MyD88-associated ALF with the ATP-binding site of TAK1 as a potential therapeutic target.
Collapse
|
6
|
Balti M, Efrit ML, Leadbeater NE. Preparation of vinyl ethers using a Wittig approach, and their subsequent hydrogenation employing continuous-flow processing. Tetrahedron Lett 2016. [DOI: 10.1016/j.tetlet.2016.03.037] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
7
|
Fakhouri L, El-Elimat T, Hurst DP, Reggio PH, Pearce CJ, Oberlies NH, Croatt MP. Isolation, semisynthesis, covalent docking and transforming growth factor beta-activated kinase 1 (TAK1)-inhibitory activities of (5Z)-7-oxozeaenol analogues. Bioorg Med Chem 2015; 23:6993-9. [PMID: 26481152 DOI: 10.1016/j.bmc.2015.09.037] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2015] [Revised: 09/14/2015] [Accepted: 09/22/2015] [Indexed: 12/22/2022]
Abstract
(5Z)-7-Oxozeanol and related analogues were isolated and screened to explore their activity as TAK1 inhibitors. Seven analogues were synthesized and more than a score of natural products isolated that examined the role that different areas of the molecule contribute to TAK1 inhibition. A novel nonaromatic difluoro-derivative was synthesized that had similar potency compared to the lead. This is the first example of a nonaromatic compound in this class to have TAK1 inhibition. Covalent docking for the isolated and synthesized analogues was carried out and found a strong correlation between the observed activities and the calculated binding.
Collapse
Affiliation(s)
- Lara Fakhouri
- Department of Chemistry and Biochemistry, Natural Products and Drug Discovery Center, University of North Carolina at Greensboro, Greensboro, NC 27402, USA
| | - Tamam El-Elimat
- Department of Chemistry and Biochemistry, Natural Products and Drug Discovery Center, University of North Carolina at Greensboro, Greensboro, NC 27402, USA
| | - Dow P Hurst
- Department of Chemistry and Biochemistry, Natural Products and Drug Discovery Center, University of North Carolina at Greensboro, Greensboro, NC 27402, USA
| | - Patricia H Reggio
- Department of Chemistry and Biochemistry, Natural Products and Drug Discovery Center, University of North Carolina at Greensboro, Greensboro, NC 27402, USA
| | - Cedric J Pearce
- Mycosynthetix, Inc., 505 Meadowlands Drive, Suite 103, Hillsborough, USA
| | - Nicholas H Oberlies
- Department of Chemistry and Biochemistry, Natural Products and Drug Discovery Center, University of North Carolina at Greensboro, Greensboro, NC 27402, USA
| | - Mitchell P Croatt
- Department of Chemistry and Biochemistry, Natural Products and Drug Discovery Center, University of North Carolina at Greensboro, Greensboro, NC 27402, USA
| |
Collapse
|
8
|
Xu J, Ong EH, Hill J, Chen A, Chai CL. Design, synthesis and biological evaluation of FLT3 covalent inhibitors with a resorcylic acid core. Bioorg Med Chem 2014; 22:6625-6637. [DOI: 10.1016/j.bmc.2014.10.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2014] [Revised: 10/06/2014] [Accepted: 10/07/2014] [Indexed: 11/16/2022]
|
9
|
Xu LX, Xue JH, Wu P, You XY, Wei XY. Absolute configurations of four resorcylic acid lactones, paecilomycins J-M, by CD/TDDFT calculations. Chirality 2013; 26:44-50. [PMID: 24408852 DOI: 10.1002/chir.22264] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2013] [Accepted: 10/08/2013] [Indexed: 11/10/2022]
Abstract
The absolute configurations of four resorcylic acid lactones (RALs), paecilomycins J-M (1-3 and 5), were assigned by Time-Dependent Density-Functional Theory (TDDFT) calculations of their electronic circular dichroism (CD) spectra. The previously reported structure 4 for paecilomycin M was found to be incorrect and should be changed to structure 5. Analysis of structure-spectrum relationship for this group of RALs suggested that V'-shape conformations give type I CD spectra (two negative Cotton effects around 300 and 260 nm, a positive Cotton effect around 220 nm) while V-shape conformations yield type II spectra (signs of three Cotton effects were opposite to those in type I).
Collapse
Affiliation(s)
- Liang-Xiong Xu
- Key Laboratory of Plant Resources Conservation and Sustainable Utilization, South China Botanical Garden, Chinese Academy of Sciences, Guangzhou, China
| | | | | | | | | |
Collapse
|
10
|
Ikemori-Kawada M, Inoue A, Goto M, Wang YJ, Kawakami Y. Docking Simulation Study and Kinase Selectivity of f152A1 and Its Analogs. J Chem Inf Model 2012; 52:2059-68. [DOI: 10.1021/ci300135g] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Megumi Ikemori-Kawada
- Eisai Tsukuba Research Laboratories, 1-3, Tokodai 5-chome, Tsukuba-shi, Ibaraki
300-2635, Japan
| | - Atsushi Inoue
- Eisai Tsukuba Research Laboratories, 1-3, Tokodai 5-chome, Tsukuba-shi, Ibaraki
300-2635, Japan
| | - Masaki Goto
- Eisai Tsukuba Research Laboratories, 1-3, Tokodai 5-chome, Tsukuba-shi, Ibaraki
300-2635, Japan
| | - Yuan John Wang
- H3 Biomedicine Inc.,300 Technology Square, Cambridge,
Massachusetts
02139, United States
| | - Yoshiyuki Kawakami
- Eisai Tsukuba Research Laboratories, 1-3, Tokodai 5-chome, Tsukuba-shi, Ibaraki
300-2635, Japan
| |
Collapse
|
11
|
Napolitano C, Palwai VR, Eriksson LA, Murphy PV. Synthesis, kinase activity and molecular modeling of a resorcylic acid lactone incorporating an amide and a trans-enone in the macrocycle. Tetrahedron 2012. [DOI: 10.1016/j.tet.2012.04.082] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
12
|
Galvez-Llompart M, Zanni R, García-Domenech R. Modeling natural anti-inflammatory compounds by molecular topology. Int J Mol Sci 2011; 12:9481-503. [PMID: 22272145 PMCID: PMC3257142 DOI: 10.3390/ijms12129481] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2011] [Revised: 12/08/2011] [Accepted: 12/09/2011] [Indexed: 12/25/2022] Open
Abstract
One of the main pharmacological problems today in the treatment of chronic inflammation diseases consists of the fact that anti-inflammatory drugs usually exhibit side effects. The natural products offer a great hope in the identification of bioactive lead compounds and their development into drugs for treating inflammatory diseases. Computer-aided drug design has proved to be a very useful tool for discovering new drugs and, specifically, Molecular Topology has become a good technique for such a goal. A topological-mathematical model, obtained by linear discriminant analysis, has been developed for the search of new anti-inflammatory natural compounds. An external validation obtained with the remaining compounds (those not used in building up the model), has been carried out. Finally, a virtual screening on natural products was performed and 74 compounds showed actual anti-inflammatory activity. From them, 54 had been previously described as anti-inflammatory in the literature. This can be seen as a plus in the model validation and as a reinforcement of the role of Molecular Topology as an efficient tool for the discovery of new anti-inflammatory natural compounds.
Collapse
Affiliation(s)
- María Galvez-Llompart
- Molecular Connectivity & Drug Design Research Unit, Department of Physical Chemistry, Faculty of Pharmacy, University of Valencia, Avenida V.A. Estelles s/n, Burjasot, Valencia 46100, Spain; E-Mails: (M.G.-L.); (R.Z.)
| | - Riccardo Zanni
- Molecular Connectivity & Drug Design Research Unit, Department of Physical Chemistry, Faculty of Pharmacy, University of Valencia, Avenida V.A. Estelles s/n, Burjasot, Valencia 46100, Spain; E-Mails: (M.G.-L.); (R.Z.)
- Department of Pharmacology, Faculty of Pharmacy, University of Bologna, Via Irnerio, Bologna 48-40126, Italy
| | - Ramón García-Domenech
- Molecular Connectivity & Drug Design Research Unit, Department of Physical Chemistry, Faculty of Pharmacy, University of Valencia, Avenida V.A. Estelles s/n, Burjasot, Valencia 46100, Spain; E-Mails: (M.G.-L.); (R.Z.)
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +34-963544291; Fax: +34-963544892
| |
Collapse
|
13
|
Sugiyama S, Fuse S, Takahashi T. Three-component coupling approach toward the synthesis of a resorcylic acid lactone framework. Tetrahedron 2011. [DOI: 10.1016/j.tet.2011.05.023] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
14
|
Gálvez-Llompart M, Recio MC, García-Domenech R. Topological virtual screening: a way to find new compounds active in ulcerative colitis by inhibiting NF-κB. Mol Divers 2011; 15:917-26. [PMID: 21717125 DOI: 10.1007/s11030-011-9323-4] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2011] [Accepted: 06/13/2011] [Indexed: 12/14/2022]
Abstract
Ulcerative colitis and Crohn's disease are chronic, immune-mediated inflammatory diseases of the gastrointestinal tract. Nuclear Factor Kappa B (NF-κB) is a transcription factor that plays a key role in regulating expression of multiple inflammatory and immune genes. In this study, a Topological Virtual Screening study has been carried out to achieve a model capable of finding new compounds active in ulcerative colitis by inhibiting NF-κB. Different topological indices were used as structural descriptors, and their relation to biological activity was determined using linear discriminant analysis. A topological model consisting of two discriminant functions was built up. The first function focused in the discrimination between NF-κB active and inactive compounds, and the second one in distinguishing between compounds active and inactive on ulcerative colitis. The model was then applied sequentially to a large database of compounds with unknown activity. Twenty-eight of such compounds were predicted to be active and selected for in vitro and in vivo testing.
Collapse
Affiliation(s)
- María Gálvez-Llompart
- Molecular Connectivity and Drug Design Research Unit, Department of Physical Chemistry, Faculty of Pharmacy, University of Valencia, Avda. VA Estellés, s/n, 46100 Burjassot, Valencia, Spain
| | | | | |
Collapse
|
15
|
Napolitano C, Natoni A, Santocanale C, Evensen L, Lorens JB, Murphy PV. Isosteric replacement of the Z-enone with haloethyl ketone and E-enone in a resorcylic acid lactone series and biological evaluation. Bioorg Med Chem Lett 2011; 21:1167-70. [DOI: 10.1016/j.bmcl.2010.12.100] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2010] [Revised: 12/17/2010] [Accepted: 12/21/2010] [Indexed: 10/18/2022]
|
16
|
Liniger M, Neuhaus C, Hofmann T, Fransioli-Ignazio L, Jordi M, Drueckes P, Trappe J, Fabbro D, Altmann KH. Kinase inhibition by deoxy analogues of the resorcylic lactone L-783277. ACS Med Chem Lett 2011; 2:22-7. [PMID: 24900250 DOI: 10.1021/ml1001807] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2010] [Accepted: 09/23/2010] [Indexed: 12/22/2022] Open
Abstract
The natural product L-783277 is a resorcylic lactone type covalent kinase inhibitor. We have prepared the 5'-deoxy analogue of L-783277 (1) in a stereoselective fashion. Remarkably, this analogue retains almost the full kinase inhibitory potential of natural L-783277, with low nanomolar IC50 values against the most sensitive kinases, and it exhibits essentially the same selectivity profile (within the panel of 39 kinases investigated). In contrast, removal of both the 4'- and the 5'-hydroxyl groups leads to a more significant reduction in kinase inhibitory activity and so does a change in the geometry of the C7'-C8' double bond in 1 from Z to E. These findings offer new perspectives for the design of second generation resorcylic lactone-based kinase inhibitors.
Collapse
Affiliation(s)
- Marc Liniger
- Swiss Federal Institute of Technology (ETH) Zurich, Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, 8093 Zurich, Switzerland
| | - Christian Neuhaus
- Swiss Federal Institute of Technology (ETH) Zurich, Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, 8093 Zurich, Switzerland
| | - Tatjana Hofmann
- Swiss Federal Institute of Technology (ETH) Zurich, Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, 8093 Zurich, Switzerland
| | - Luca Fransioli-Ignazio
- Swiss Federal Institute of Technology (ETH) Zurich, Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, 8093 Zurich, Switzerland
| | - Michel Jordi
- Swiss Federal Institute of Technology (ETH) Zurich, Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, 8093 Zurich, Switzerland
| | - Peter Drueckes
- Novartis Institute for Biomedical Research, Center for Proteomic Chemistry, Expertise Platform Kinases, 4002 Basel, Switzerland
| | - Jörg Trappe
- Novartis Institute for Biomedical Research, Center for Proteomic Chemistry, Expertise Platform Kinases, 4002 Basel, Switzerland
| | - Doriano Fabbro
- Novartis Institute for Biomedical Research, Center for Proteomic Chemistry, Expertise Platform Kinases, 4002 Basel, Switzerland
| | - Karl-Heinz Altmann
- Swiss Federal Institute of Technology (ETH) Zurich, Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, 8093 Zurich, Switzerland
| |
Collapse
|
17
|
Jogireddy R, Barluenga S, Winssinger N. Molecular editing of kinase-targeting resorcylic acid lactones (RAL): Fluoroenone RAL. ChemMedChem 2010; 5:670-3. [PMID: 20209566 DOI: 10.1002/cmdc.201000047] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
18
|
Barluenga S, Jogireddy R, Koripelly GK, Winssinger N. In Vivo Efficacy of Natural Product-Inspired Irreversible Kinase Inhibitors. Chembiochem 2010; 11:1692-9. [DOI: 10.1002/cbic.201000205] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
19
|
Shen Y, Boivin R, Yoneda N, Du H, Schiller S, Matsushima T, Goto M, Shirota H, Gusovsky F, Lemelin C, Jiang Y, Zhang Z, Pelletier R, Ikemori-Kawada M, Kawakami Y, Inoue A, Schnaderbeck M, Wang Y. Discovery of anti-inflammatory clinical candidate E6201, inspired from resorcylic lactone LL-Z1640-2, III. Bioorg Med Chem Lett 2010; 20:3155-7. [DOI: 10.1016/j.bmcl.2010.03.087] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2010] [Revised: 03/20/2010] [Accepted: 03/26/2010] [Indexed: 10/19/2022]
|
20
|
Shen Y, Du H, Kotake M, Matsushima T, Goto M, Shirota H, Gusovsky F, Li X, Jiang Y, Schiller S, Spyvee M, Davis H, Zhang Z, Pelletier R, Ikemori-Kawada M, Kawakami Y, Inoue A, Wang Y. Discovery of an in vitro and in vivo potent resorcylic lactone analog of LL-Z1640-2 as anti-inflammatory lead, II. Bioorg Med Chem Lett 2010; 20:3047-9. [PMID: 20427182 DOI: 10.1016/j.bmcl.2010.03.119] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2010] [Revised: 03/26/2010] [Accepted: 03/31/2010] [Indexed: 10/19/2022]
Abstract
The potent in vitro lead compound, ER-803064 (2), a MEK1 and MEKK1 inhibitor inspired from natural product LL-Z1640-2 (f152A1), was further optimized to improve in vitro and in vivo potency. The modifications on C14 position led to discovery of the lead compounds 28 and 29, which regained full in vitro potency of f152A1 and showed higher in vivo potency by iv administration.
Collapse
|